Clinical trial
Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in…
NCT01897571 · Epizyme, Inc., Industry · Completed
Key facts
| NCT number | NCT01897571 |
|---|---|
| Title | Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCL |
| Official title | An Open-Label, Multicenter, Phase 1/2 Study of Tazemetostat as a Single Agent in Subjects With Advanced Solid Tumors or With B-cell Lymphomas and Tazemetostat in Combination With Prednisolone in Subjects With Diffuse Large B Cell Lymphoma |
| Lead sponsor | Epizyme, Inc., Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | B-cell Lymphomas (Phase 1), Advanced Solid Tumors (Phase 1), Diffuse Large B-cell Lymphoma (Phase 2), Follicular Lymphoma (Phase 2), Transformed Follicular Lymphoma, Primary Mediastinal Large B-Cell Lymphoma |
| Intervention type | Drug |
| Interventions | Tazemetostat, Prednisolone |
| Enrollment | 400 |
| Start date | Jun 13, 2013 |
| Primary completion | Aug 24, 2021 |
| Completion | Nov 2, 2021 |
| First posted | Jul 12, 2013 |
| Last update posted | Mar 26, 2024 |
| Countries | Australia, Canada, France, Germany, Italy, Poland, Taiwan, Ukraine, United Kingdom, United States |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: